

Ref. No: 1736  
Date: 08/05/25  
Subject: intra-vitreous injections or implants

## REQUEST & RESPONSE

1. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from January to April 2025:

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Faricimab
- Fluocinolone acetonide
- Ranibizumab - Lucentis
- Ranibizumab - Biosimilar (Ongavia, Ximluci, Byooviz, Rimmyrah)

Please provide the number of injections/implants by eye condition for the four-month period from January to April 2025:

Number of Injections/Implants: January to April 2025:

| Treatment   | Eye Conditions                              |                               |                              |
|---|---|-------------------------------|------------------------------|
|   | Wet Age-Related Macular Degeneration (wAMD) | Diabetic Macular Oedema (DMO) | Retinal Vein Occlusion (RVO) |
| Aflibercept   | 759   | 116                           | 148                          |
| Bevacizumab   | 0   | 0                             | 0                            |
| Dexamethasone   | 0   | <5                            | 22                           |
| Faricimab   | 585   | 113                           | <5                           |
| Ranibizumab - Lucentis                                      | 0   | 0                             | <5                           |
| Ranibizumab - Ongavia (Ongavia, Ximluci, Byooviz, Rimmyrah) | 291   | 12                            | 42                           |